Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Working Capital Changes (2020 - 2025)

Historic Other Working Capital Changes for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $4.6 million.

  • Mirum Pharmaceuticals' Other Working Capital Changes rose 2059.36% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 million, marking a year-over-year increase of 61243.18%. This contributed to the annual value of $1.5 million for FY2024, which is 5838.89% down from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Other Working Capital Changes of $4.6 million as of Q3 2025, which was up 2059.36% from $4.1 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Other Working Capital Changes high stood at $4.6 million for Q3 2025, and its period low was -$2.1 million during Q2 2022.
  • Over the past 5 years, Mirum Pharmaceuticals' median Other Working Capital Changes value was $1.1 million (recorded in 2023), while the average stood at $1.3 million.
  • In the last 5 years, Mirum Pharmaceuticals' Other Working Capital Changes skyrocketed by 128125.0% in 2021 and then plummeted by 34282.74% in 2022.
  • Mirum Pharmaceuticals' Other Working Capital Changes (Quarter) stood at $1.8 million in 2021, then grew by 14.14% to $2.0 million in 2022, then tumbled by 92.42% to $153000.0 in 2023, then plummeted by 98.69% to $2000.0 in 2024, then surged by 231500.0% to $4.6 million in 2025.
  • Its Other Working Capital Changes stands at $4.6 million for Q3 2025, versus $4.1 million for Q2 2025 and $3.0 million for Q1 2025.